Evidence map›Paper›PMID 39648250›Full record

ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2025

Phenotypic patterns and response to immunotherapy in a group of Very Late Onset Myasthenia Gravis: a single center study.

Aigli G Vakrakou, Eleni Strataki, Loukas Lymperopoulos, Dimitrios Panaretos, Vasiliki Zouvelou

Abstract read
PubMed Publisher
In one paragraph

Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Aigli G Vakrakou1st Neurology Department, Aeginition Hospital, National and Kapodistrian University of Athens, 74 Vas. Sophias Ave., 11528, Athens, Greece.
Eleni Strataki1st Neurology Department, Aeginition Hospital, National and Kapodistrian University of Athens, 74 Vas. Sophias Ave., 11528, Athens, Greece.
Loukas Lymperopoulos1st Neurology Department, Aeginition Hospital, National and Kapodistrian University of Athens, 74 Vas. Sophias Ave., 11528, Athens, Greece.
Dimitrios PanaretosDepartment of Statistics and Insurance Science, School of Economic Sciences, University of Western Macedonia, Kozani, Greece.
Vasiliki Zouvelou1st Neurology Department, Aeginition Hospital, National and Kapodistrian University of Athens, 74 Vas. Sophias Ave., 11528, Athens, Greece. vzouvelu@med.uoa.gr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimsThe goal of this study was to assess the clinical profile of myasthenia gravis (MG) in patients diagnosed above 65-years of age (VLOMG) and identify clinical/serological parameters associated with their MG status and prognosis.

methodsThis was a retrospective assessment of consecutive patients with VLOMG (n = 70) Demographics, clinical characteristics, medical comorbidities, the Myasthenia Gravis Foundation of America (MGFA) severity scale scores, and MGFA Post-Intervention Status (MGFA-PIS) were collected.

resultsThe research population was diagnosed with MG at an average age of 73.16 ± 6.33 years, a male/female ratio of 2.3/1 and a mean follow-up time of 53.09 ± 46.37 months. The titer of acetylcholine receptor antibodies (AChR Abs) was positive at 95.71% of patients. The predominant distribution of myasthenic weakness was oculobulbar (63.79%). At the last follow-up, 75.71% of patients reached Pharmacological-Remission (PR) or Minimal-Manifestations (MM), 17% manifested improvement and 7.14% were clinically unchanged, worse or dead, according to MGFA-PIS. Most patients responded to low doses of steroids. Males and patients with generalized muscle involvement upon disease-onset were more likely to reach PR or MM than females or ocular presentation (OR = 3.84 and O.18, respectively). Six patients (8.57%) were treated with at least one cycle of rituximab due to disease severity. Five (83%) reached PR or MM and one improved (mean follow up time: 7.5 months).

interpretationWe found that patients with VLOMG are usually males, with oculobulbar muscle involvement and positive titer of AChR Abs. The majority had a favorable prognosis and an adequate response to low doses of prednisolone and long-term immunosuppression.

Indexed as

ImmunotherapyMyasthenia GravisAgedAged, 80 and overAge of OnsetAutoantibodiesFemaleFollow-Up StudiesHumansMalePhenotypeReceptors, CholinergicRetrospective StudiesSeverity of Illness IndexTreatment OutcomeAutoantibodiesReceptors, CholinergicAChR antibodiesMyasthenia gravisOculobulbarRituximabSteroidsVery late onset

Identifiers

PMID39648250

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.